27-02-2023, 18:53

Bright Minds Biosciences Provides Clinical Program Updates

-- First-in-human Phase 1 trial for lead program, BMB-101, a highly selective 5-HT2C agonist, is underway in Australia
Globe Newswire27-02-2023, 18:53
17-02-2023, 18:52

Bright Minds Biosciences Announces Non-Executive Director

David Weiner, MD, brings extensive experience in the discovery and clinical development of novel therapeutics for
Globe Newswire17-02-2023, 18:52